Abstracts

132 – Effect of Different Pharmacy PrEP Delivery Models on Initiation and Continuation in Kenya: A cRCT

Background In many parts of Africa, private pharmacies are prevalent and commonly accessed but underutilized for PrEP and PEP delivery. Evidence on specific implementation strategies to operationalize pharmacy delivery is lacking.  Methods The Pharm PrEP cRCT (NCT05842122) randomized 60 pharmacies across 6 Kenyan counties 1:1:1:1 to 4 arms (A): A1) client-sustained delivery: clients (age 16+) paid pharmacies…

140 – Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT

Background Budigalimab and trosunilimab are recombinant IgG1 monoclonal antibodies that bind cell-surface expressed PD-1 receptor and α4β7 integrin, respectively. In people with HIV (PWH), it is hypothesized that the two may act synergistically to boost HIV-specific T-cell responses, leading to enhanced immuno-surveillance enabling ART-free viral control. This phase 2 study evaluated the safety and efficacy of…

148 – Safety and Treatment Completion of 1HP Versus 3HP in People With HIV: The One-to-Three Trial

Background Short-course tuberculosis (TB) preventive treatment (TPT) using rifapentine and isoniazid either weekly for 12 weeks (3HP) or daily for one month (1HP) is effective in people with HIV (PWH), but comparative safety and treatment completion data are limited. We compared safety and treatment completion of self-administered 1HP and 3HP among PWH virally suppressed on dolutegravir-based…

149 – Novel Linezolid Dosing With Bedaquiline, Delamanid, and Clofazimine for Drug-Resistant TB Treatment

Background Background: Short-course treatment (Rx) for drug-resistant TB (DR-TB) includes linezolid (LZD) as a key component but optimal LZD doses that maximize anti-TB activity and minimize toxicity are not established. ACTG A5356 is a Ph2 randomized, open-label trial of 26 wks of Rx for DR-TB with novel high vs standard dose LZD plus simplified bedaquiline (BDQ),…

152 – Viral Control Among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies

Background Broadly neutralizing antibodies (bNAbs) may reduce viral reservoir and promote post-treatment HIV control; establishing their ability to sustain viral suppression is an essential first step toward the goal of drug-free remission. The Tatelo Study found nearly half of unscreened children on ART since birth remained suppressed on dual bNAbs alone (10-1074 and VRC01LS). In…

163 – The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda

Background HIV incidence remains above global targets despite efficacious prevention and treatment products. We hypothesized that a SEARCH Community Precision Health intervention – using technology to connect people to HIV testing, prevention and treatment from community to clinic and back – would reduce population-level HIV incidence. Methods We conducted a cluster randomized controlled trial in…

172 – Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART

Background Recent studies revealed discrete footprints of immune selection in the HIV reservoir cell pool, implying that human immune responses may be able to effectively engage and target these cells. However, the immune mechanisms driving the selection of reservoir cells remain unknown. Methods We performed single-genome, near full-length proviral next-generation sequencing to assess the frequencies…

177 – DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study

Background Doravirine (DOR) and islatravir (ISL; a nucleoside reverse transcriptase translocation inhibitor) are being studied in combination for the treatment of HIV. In people with virologically suppressed HIV-1, the efficacy of switching to DOR/ISL (100/0.25mg) was non-inferior to continuing prior antiretroviral therapy in 2 phase 3 studies. We report the efficacy and safety of DOR/ISL…